Spain continues reduction of pharma spending and starts adopting value based pricing

4 February 2014

The Spanish Ministry of Health last week announced pharmaceutical spending data, which showed a new drop in 2013. Last year, the National Health System (SNS) spent 9.18 billion euros ($12.38 billion), 587.69 million euros less than the previous year (-6.1%), reports The Pharma Letter’s local correspondent. This compares with 2011, when savings increased to near 2 billion euros (-17.5%).

Official data also showed a decrease in the number of prescriptions in 2013, with doctors signing 859.5 millions scripts last year, 54.1 million less than in 2012 and 113 million less than 2011. The latest data show the achievement of savings goals linked to new measures approved in Royal-Decree 16/2012, which introduced delisting measures and changes in co-payments for medicines to a “fairer system,” according to official government statements.

Generics continue to gain market share

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK